Immune Mechanism Research of Shengxian Decoction on Rats with Experimental Autoimmune Myasthenia Gravis

Jie ZHU,Yang CHENG,Junyao XU,Zhouye WU,Yidi CHEN,Gang CHEN,Haoxin WU
DOI: https://doi.org/10.13193/j.issn.1673-7717.2017.03.058
2017-01-01
Abstract:Objective:To explore the immune mechanism of Shengxian Decoction treating rats with experimental autoimmune myasthenia gravis(EAMG).Methods:Lewis rats were made into the model of EAMG by injecting the artificially synthesized peptide derived from the rats' sequence 97-116 of the AChR a subunit (R97-116),and further divided into the adjuvant control group,the model control group,western medicine control group(Prednisone),Shengxian Decoction low,middle and high dose groups after successful model evaluation.And then the electromyography,acetylcholine receptor antibody(AChR-Ab) titer,IFN-γ content,the levels of CD4+ and CD8+ lymphocyte in peripheral blood and CD4+/CD8+ proportion in rats after receiving one-month treatment were tested and calculated.Results:Compared with the adjuvant control group,the levels of AChR-Ab and IFN-γ in the model groups both went up evidently(P < 0.05)while compared with the model control group,the levels of AChR-Ab and IFN-γ in the treatment groups both declined notably(P <0.05).Compared with the adjuvant control group,the CD4+/CD8+ proportion in the model groups went up evidently(P <0.01) and the proportion among Shengxian Decoction low and middle dose groups tended to decline.CD4+ and CD8+ levels and CD4+/CD8+ proportion in the western medicine control group all went down evidently(P <0.01).Conclusion:Shengxian Decoction can inhibit the synthesis of AChR-Ab or promote its degradation by decreasing CD4+ /CD8+ proportion and IFN-γ content so as to reach the function of treating rats with EAMG.
What problem does this paper attempt to address?